Abbrea Capital’s Biogen BIIB Stock Holding History

Abbrea Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-710	Closed	-$222K	–	154
2017 Q3	$222K	Buy	+710	New	+$210K	0.08%	144

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Abbrea Capital's BIIB Position: Q4 2017 in Review

Abbrea Capital sold out of Biogen (BIIB) in Q4 2017, closing a stake of 710 shares — an estimated $222K sold.

Abbrea Capital first reported a position in BIIB in Q3 2017 and held it in 1 quarter. The position peaked at $222K in Q3 2017. 1,122 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

Abbrea Capital reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
Abbrea Capital sold 710 Biogen shares in Q4 2017, an estimated $222K.
Abbrea Capital first reported a position in Biogen in Q3 2017 and held it in 1 quarter.
Abbrea Capital's Biogen position peaked at $222K in Q3 2017.
1,122 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Abbrea Capital's 13F filing for Q4 2017, filed 1 Feb 2018.